These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
259 related articles for article (PubMed ID: 7849420)
1. Preliminary experimental anticancer activity of cecropins. Moore AJ; Devine DA; Bibby MC Pept Res; 1994; 7(5):265-9. PubMed ID: 7849420 [TBL] [Abstract][Full Text] [Related]
2. In vitro characterization of the anticancer activity of membrane-active cationic peptides. I. Peptide-mediated cytotoxicity and peptide-enhanced cytotoxic activity of doxorubicin against wild-type and p-glycoprotein over-expressing tumor cell lines. Johnstone SA; Gelmon K; Mayer LD; Hancock RE; Bally MB Anticancer Drug Des; 2000 Apr; 15(2):151-60. PubMed ID: 10901303 [TBL] [Abstract][Full Text] [Related]
3. Antimicrobial activity of cecropins. Moore AJ; Beazley WD; Bibby MC; Devine DA J Antimicrob Chemother; 1996 Jun; 37(6):1077-89. PubMed ID: 8836811 [TBL] [Abstract][Full Text] [Related]
4. (R,R)-2,2'-[1,2-ethanediylbis[imino(1-methyl-2,1-ethanediyl)]]- bis[5-nitro-1H-benz[de]isoquinoline-1,3-(2H)-dione] dimethanesulfonate (DMP 840), a novel bis-naphthalimide with potent nonselective tumoricidal activity in vitro. Kirshenbaum MR; Chen SF; Behrens CH; Papp LM; Stafford MM; Sun JH; Behrens DL; Fredericks JR; Polkus ST; Sipple P Cancer Res; 1994 Apr; 54(8):2199-206. PubMed ID: 8174127 [TBL] [Abstract][Full Text] [Related]
5. Novel phosphonium salts display in vitro and in vivo cytotoxic activity against human ovarian cancer cell lines. Manetta A; Gamboa G; Nasseri A; Podnos YD; Emma D; Dorion G; Rawlings L; Carpenter PM; Bustamante A; Patel J; Rideout D Gynecol Oncol; 1996 Feb; 60(2):203-12. PubMed ID: 8631539 [TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts. Gourdeau H; Genne P; Kadhim S; Bibeau L; Duchamp O; Ouellet F; deMuys JM; Bouffard DY; Attardo G Cancer Chemother Pharmacol; 2002 Dec; 50(6):490-6. PubMed ID: 12451476 [TBL] [Abstract][Full Text] [Related]
7. In vivo antitumor activity and host toxicity of methoxymorpholinyl doxorubicin: role of cytochrome P450 3A. Quintieri L; Rosato A; Napoli E; Sola F; Geroni C; Floreani M; Zanovello P Cancer Res; 2000 Jun; 60(12):3232-8. PubMed ID: 10866316 [TBL] [Abstract][Full Text] [Related]
8. Structure and function of a custom anticancer peptide, CB1a. Wu JM; Jan PS; Yu HC; Haung HY; Fang HJ; Chang YI; Cheng JW; Chen HM Peptides; 2009 May; 30(5):839-48. PubMed ID: 19428759 [TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of imidazothioxanthones in murine and human tumor models in vitro and in vivo. Varvaresou A; Iakovou K; Gikas E; Fichtner I; Fiebig HH; Kelland LR; Double JA; Bibby MC; Hendriks HR Anticancer Res; 2004; 24(2B):907-19. PubMed ID: 15161044 [TBL] [Abstract][Full Text] [Related]
10. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models. Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998 [TBL] [Abstract][Full Text] [Related]
11. Anticancer efficacy of Magainin2 and analogue peptides. Baker MA; Maloy WL; Zasloff M; Jacob LS Cancer Res; 1993 Jul; 53(13):3052-7. PubMed ID: 8319212 [TBL] [Abstract][Full Text] [Related]
12. 4-Demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548), a novel anticancer agent active against tumor cell lines with different resistance mechanisms. Marchini S; Damia G; Broggini M; Pennella G; Ripamonti M; Marsiglio A; Geroni C Cancer Res; 2001 Mar; 61(5):1991-5. PubMed ID: 11280757 [TBL] [Abstract][Full Text] [Related]
13. 8,11-dihydroxy-6-[(aminoalkyl)amino]-7H-benzo[e]perimidin-7-ones with activity in multidrug-resistant cell lines: synthesis and antitumor evaluation. Stefańska B; Dzieduszycka M; Bontemps-Gracz MM; Borowski E; Martelli S; Supino R; Pratesi G; De Cesare M; Zunino F; Kuśnierczyk H; Radzikowski C J Med Chem; 1999 Sep; 42(18):3494-501. PubMed ID: 10479282 [TBL] [Abstract][Full Text] [Related]
14. Cecropin D-like antibacterial peptides from the sphingid moth, Agrius convolvuli. Lee IH; Chang KY; Choi CS; Kim HR Arch Insect Biochem Physiol; 1999; 41(4):178-85. PubMed ID: 10421892 [TBL] [Abstract][Full Text] [Related]
15. MST-16, a novel bis-dioxopiperazine anticancer agent, ameliorates doxorubicin-induced acute toxicity while maintaining antitumor efficacy. Yoshida M; Maehara Y; Sugimachi K Clin Cancer Res; 1999 Dec; 5(12):4295-300. PubMed ID: 10632373 [TBL] [Abstract][Full Text] [Related]
16. Novel multidrug resistance reversal agents. Berger D; Citarella R; Dutia M; Greenberger L; Hallett W; Paul R; Powell D J Med Chem; 1999 Jun; 42(12):2145-61. PubMed ID: 10377220 [TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo pharmacological characterizations of the antitumor properties of two new olivacine derivatives, S16020-2 and S30972-1. Malonne H; Farinelle S; Decaestecker C; Gordower L; Fontaine J; Chaminade F; Saucier JM; Atassi G; Kiss R Clin Cancer Res; 2000 Sep; 6(9):3774-82. PubMed ID: 10999772 [TBL] [Abstract][Full Text] [Related]
18. Pseudolaric acid B, a novel microtubule-destabilizing agent that circumvents multidrug resistance phenotype and exhibits antitumor activity in vivo. Wong VK; Chiu P; Chung SS; Chow LM; Zhao YZ; Yang BB; Ko BC Clin Cancer Res; 2005 Aug; 11(16):6002-11. PubMed ID: 16115945 [TBL] [Abstract][Full Text] [Related]